Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model

Author：                

Publisher： Spandidos Publications

E-ISSN： 1791-2423|47|1|377-383

ISSN： 1019-6439

Source： International Journal of Oncology, Vol.47, Iss.1, 2015-01, pp. : 377-383

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

By        

International Journal of Oncology, Vol. 43, Iss. 5, 2013-01 ,pp. : 1627-1635

Spandidos Publications

Access to resources Recommend Favorite

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

By Cirone Pasquale   Andresen Catharine   Eswaraka Jeetendra   Lappin Patrick   Bagi Cedo  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 525-538

Springer Publishing Company

Access to resources Recommend Favorite

The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells

By            

Molecular Medicine Reports, Vol. 5, Iss. 2, 2012-01 ,pp. : 503-508

Spandidos Publications

Access to resources Recommend Favorite

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

By            

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 253-260

Spandidos Publications

Access to resources Recommend Favorite